口服氟喹诺酮与主动脉瓣或二尖瓣反流风险:全国性巢式病例对照研究
该研究基于丹麦全国2005–2018年登记数据,采用巢式病例对照设计,纳入38 370例瓣膜反流病例和1 115 100名匹配对照。以青霉素V为对照,口服氟喹诺酮暴露与主动脉瓣或二尖瓣反流风险无显著关联(HR 1.02,95%CI 0.95–1.09),累积剂量分析结果一致。
要点
- 口服氟喹诺酮与主动脉瓣或二尖瓣反流风险无显著关联。
- 累积剂量增加亦未见显著关联,如cDDD>10对比1–5的HR为1.08(95%CI 0.95–1.23)。
- 结果在高血压亚组及以瓣膜手术定义病例的分析中一致。
核心结论
- 在全国性巢式病例对照研究中,口服氟喹诺酮与瓣膜反流风险无显著关联,不支持两者存在因果联系。
研究设计与样本
- 基于丹麦行政登记数据,2005–2018年全国队列中开展巢式病例对照研究,病例为首次发生主动脉瓣或二尖瓣反流,共38 370例,匹配1 115 100名对照。
主要发现
- 与青霉素V使用者相比,氟喹诺酮暴露与主动脉瓣或二尖瓣反流风险无显著关联(HR 1.02,95%CI 0.95–1.09)。
- 累积定义日剂量(cDDD)>10对比cDDD 1–5的HR为1.08(95%CI 0.95–1.23),无显著关联。
- 在高血压患者队列及以瓣膜手术定义病例的分析中结果一致。
关键数值与推荐
- 主要关联分析采用时间依赖Cox回归模型,以青霉素V为对照,报告HR及95%CI。
- 累积剂量分析示例:cDDD>10对比cDDD 1–5的HR 1.08(95%CI 0.95–1.23)。
临床怎么用
- 对于需使用口服氟喹诺酮的患者,本研究结果不支持因瓣膜反流风险而改变临床决策。
- 既往EMA安全警告所提示的关联未在本研究中重现,临床可结合患者个体情况综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Reports have suggested an increased risk of aortic and mitral regurgitation associated with oral fluoroquinolones (FQs) resulting in a safety warning published by the European Medicines Agency (EMA). However, these findings have not yet been replicated. METHODS AND RESULTS: Using Danish administrative registers, we conducted a nested case-control study in a nationwide cohort of individuals between 2005 and 2018. Cases were defined as the first occurrence of aortic or mitral regurgitation. Exposure of interest was the use of oral FQs. Hazard ratios (HRs) with 95% confidence intervals (95% CI) were obtained by fitting time-dependent Cox regression models, with penicillin V as comparator, to assess the association between FQ use and incident valvular regurgitation. We identified 38 370 cases of valvular regurgitation with 1 115 100 matched controls. FQ exposure was not significantly associated with increased rates of aortic or mitral regurgitation (HR 1.02, 95% CI 0.95-1.09) compared with penicillin V users. Investigating the cumulative defined daily doses (cDDD) of FQs yielded similar results with no significant association between increasing FQ use and valvular regurgitation (e.g. HR 1.08, 95% CI 0.95-1.23 for cDDD >10 compared with cDDD 1-5). These results were consistent across several analyses including a cohort of patients with hypertension and using a case definition based on valvular surgical interventions. CONCLUSIONS: In a nationwide nested case-control study, FQs were not significantly associated with increased rates of valvular regurgitation. Our findings do not support a possible causal connection between FQ exposure and incident valvular regurgitation.
引用
- Strange JE, Holt A, Blanche P, et al. Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study. Eur Heart J. 2021. PMID: 34245252. doi:10.1093/eurheartj/ehab374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。